Strand Therapeutics Secures $153 Million in Series B Funding to Advance mRNA Therapies
Innovative biotech startup Strand Therapeutics has successfully closed a major funding round of $153 million in Series B financing, led by Swedish investment firm Kinnevik and supported by several investors and new partners. This brings the total investments secured by the company to over $250 million.
This financial injection aims to accelerate the development of Strand's pipeline of programmable messenger RNA (mRNA) therapies, with STX-001 at the forefront. This therapeutic candidate, which specifically targets the tumor microenvironment by expressing IL-12 cytokine, has already demonstrated promising results in its Phase 1 study in patients with advanced solid tumors. Additionally, Strand has presented encouraging preclinical data for STX-003, a systemically administered mRNA therapy designed to attack tumors while minimizing off-target effects.
Strand's strength lies in its proprietary technology platform, which combines self-replicating and circular mRNA with sophisticated genetic circuits. This combination enables precise, durable, and localized delivery of treatments, paving the way for more targeted and personalized therapeutic approaches to complex diseases, including cancer.
